TNFRSF10B and renal carcinoma: The use of a DR5/Fc chimericprotein or DR5 siRNA attenuated rosiglitazone and TRAIL-induced apoptosis,indicating a critical role of DR5 induction in this death process.Interestingly, rosiglitazone induced the generation of ROS, whereas cotreatmentwith glutathione, which can scavenge ROS, prevented ROS generation, DR5upregulation, and enhancement of TRAIL-induced apoptosis by rosiglitazone,suggesting that ROS-mediated transcriptional activation of DR5 is important forsensitization of renal cancer cells to TRAIL-induced apoptosis [49].